Rivero LA, Núñez CM, Rivero NH, Rivero LA

Language: Spanish
References: 16
Page:
PDF size: 144.32 Kb.

ABSTRACT

A 68 year old patient, male, white skin and previous heath diabetic history is presented, he goes to external consultation at Princess Margaret Hospital of Tuvalu, this country is located to the northwest of Australia in the South Pacific Ocean, he complained approximately two months of increase of moderate volume in the brachial biceps muscle of the right arm associated to pain. Initially it was diagnosed as an original infectious lesion which never improved to the antibiotic treatment. Two weeks later he returns for progressive increase of volume and pain of the lesion, besides discreet functional impotence. It is consulted with the Cuban surgeon and he advice a cytological biopsy by puncture, which reveals the presence of malignant cells, after that it decided to practice him an incitional biopsy which diagnosed was a Pleomorphic Rhabdomyosarcoma doing total surgical exceresis, the most frequent characteristics were exposed, presentation forms of this illness and some prognostic factors. Final conclusions are given and the literature is consulted.

REFERENCES

1. Halperin E. Rhabdomyosarcoma. Incidence and mortality. Boston: Williams & Wilkins; 1999.

2. Mitchell RN, Perkin JA. Tumores del músculo esquelético. En: Compendio de Robbins y Cotran: patología estructural y funcional. Barcelona: Elsevier; 2012. p. 1310-1311.

3. Raney B, Anderson J, Barr F. Rhabdomyosarcoma and undifferentiated sarcoma: A selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V. J Hematol Oncol. 2010; 23: 215-20.

4. Breneman J, Wiener E. Histological appearance of Rhabdomyosarcoma. Med Oncol. 2010; 35: 104-9.

5. Guillou L. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group. Grading system in a population of 420 adult patients with soft tissue sarcoma. J Clin Oncol. 2010; 15:350.

6. Webb S. Rhabdomyosarcoma of childhood. New York: IOP plublishing; 2009.

7. Merchant T. Soft tissue tumors: stadistical study. A J Oncol. 1997; 7: 236-45.

8. Michalski JM, Sur RK, Harm WB. Musculoskeletal oncology: advances in cytogenetics and molecular genetic and their clinical implications. Int J Radiat Oncol Biol Phys. 2009; 33: 985- 91.

9. Breitfeld P, Meyer W. Rhabdomyosarcoma: new windows of opportunity. Oncologist [Internet]. 2005 [citado 1 Abr 2006]; 10(7): 518-27. Disponible en: http://theoncologist.alphamedpress.org/cgi/content/full/10/7/518

10. Hicks J, Flaitz C. Rhabdomyosarcoma of the muscular tissue: frecuency. Acta Oncol. 2010; 38(5): 450-9.

11. Stevens M. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol. 2011; 6(2): 77-84.

12. Lawrence JR, Anderson W, Gehan E. Pre-treatment TNM staging of rhabdomyosarcoma: a report of the Intergroup Rhabdomiosarcoma Study Group. Cancer. 2009; 80: 1165-70.

13. O'Callaghan M, House M, Ebay S, Bhadelia R. Three dimensional conformal radiation therapies in rhabdomyosarcomas. J Comput Assist Tomogr. 2010; 29(1): 130-2.

14. Schouwenburg P, Kupperman D, Bakker F, Blank L, de Boer HB, Voute T. New combined treatment of surgery, radiotherapy, and reconstruction in head and neck rhabdomyosarcoma in children: the AMORE protocol. Head Neck. 2009; 20(4): 283-92.

15. Morikawa Y. Rhabdomyosarcoma: oncologycal treatment. Nippon Geka Gakkai Zasshi. 2008; 106(7): 431-6.

16. Stevens M, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand J, et al. Treatment of nonmetastatic rhabdomyosarcoma: third study of the International Society of Oncology -SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2009; 23(12): 2586-7.